Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.

Hiroyuki TsutsuiHiroyuki SakamakiShin-Ichi MomomuraYasushi SakataYutaro KotobukiStephan LindenKoki IdeharaDaisuke Nitta

Published in: ESC heart failure (2023)

Empagliflozin was demonstrated to be cost-effective for patients with HFpEF in Japan based on EMPEROR-Preserved trial data.

Keyphrases